Giuliana Grossi

Genetic analysis finds 125 loci shared by insomnia and CRP, with Mendelian randomization favoring an effect from insomnia liability to inflammation.

HR 1 brings Medicaid work requirements and narrower immigrant eligibility by January 2027, and CBO projects 10 million more uninsured by 2034.

CMS ends ACA subsidies for 189,000 enrollees with duplicate Medicare, Medicaid, or CHIP coverage or listed as deceased, with a 30-day dispute window.

Postpartum navigation missed its primary goal but raised postpartum visits and primary care use among Medicaid-insured patients.

Nicolas Ferreyros, of COA, warns IRA drug price negotiation threatens community oncology payments and urges Part B, 340B, and insurer reforms.

Follitropin delta yields cumulative ongoing pregnancy in 64.0% of patients under 35 and 43.9% of those 35 to 42 in 2 placebo-controlled IVF trials.

Polyphenols show lab promise for endometriosis, but human evidence is thin, and the best resveratrol pain trial was negative.

Alyssa Schatz, DrPH, MSW, of NCCN, explains how insurance shifts and drug shortages threaten access to cancer care.

Teva's Weltruza, a once-monthly subcutaneous olanzapine injection, requires no loading doses, oral supplementation, or postinjection monitoring.

The FDA approves atezolizumab with a fluoropyrimidine and oxaliplatin as adjuvant therapy for stage III dMMR colon cancer based on the ATOMIC trial.

The trade group says CMS lacks authority to impose GLOBE, which is set to begin January 1.

Sacral neuromodulation is still considered the gold standard for refractory overactive bladder, with tibial nerve stimulation a less invasive option.

Mitchell Blewett, PharmD, MS, of Cleveland Clinic, explains why formulary approval is only the midpoint before a new oncology drug reaches patients.

This week in health equity and access: PMOS diagnosis, HIV lung cancer screening, transplant access, atopic dermatitis care, and value-based oncology.

Sean Wharton, MD, PharmD, discusses new data on survodutide from the phase 3 SYNCHRONIZE-2 trial.

CMS finalized the mandatory GLOBE Model, tying Part B drug rebates to international prices in areas covering 25% of beneficiaries from Jan. 1, 2027.

Survodutide achieved up to 13.1% weight loss vs 3.1% with placebo at 76 weeks in adults with obesity and T2D in the phase 3 SYNCHRONIZE-2 trial.

AASM urges CMS to reject proposed 2027 Medicare conversion factor cuts of 1.19% to 1.68% and revise sleep testing and remote monitoring policies.

Phase 3 trials found oveporexton improved wakefulness, sleepiness, and cataplexy in narcolepsy type 1, with insomnia and urinary frequency common.

Mayo Clinic's Scott Soefje, PharmD, MBA, explains how logistics, contracts, and cost shape access to new cancer drugs and high-cost drug reviews.

Caregiver shortages limit access to transplant, CAR T, and bispecific therapies, and no system offers replacement support, says Duke's Thomas LeBlanc, MD, MA.

Experts tackled CAR T access, trial equity, and overtreatment in breast cancer at an AJMC Institute for Value-Based Medicine event in San Francisco.

Even top academic centers struggle to keep pace with precision medicine, says William K. Oh, MD, who is prioritizing clinician education at Yale.

AI could ease oncology's drug development "traffic jam," while biomarker subsetting drives more personalized cancer care, David Spigel, MD, says.

NCCN concordance won't ensure coverage; OAB risk tied to income; 91% offer bispecifics; ruxolitinib spend hits $49.6M; TALK SAFE Act aids telepsychiatry.

A large propensity-matched study linked outpatient melatonin use to a small reduction in REM sleep in children evaluated for polysomnography.

Community oncology faces high costs and staffing hurdles for trials; Lucio N. Gordan, MD, urges pragmatic designs matching real-world patients.

Liquid biopsy and at-home phlebotomy are closing precision medicine access gaps nationwide, though tissue remains the gold standard.

Madhav R. Seshadri, MD, speaks on CLL's shift toward fixed-duration, MRD-guided regimens, MRD testing barriers, and open questions on drug sequencing.

Nonadherence to semaglutide for obesity worsened once out-of-pocket costs passed roughly $75 per 30-day supply among commercially insured adults.